Innovent Biologics, Inc. (IVBIY)
OTCMKTS · Delayed Price · Currency is USD
39.75
0.00 (0.00%)
At close: Jan 29, 2026
Innovent Biologics Employees
Innovent Biologics had 6,190 employees as of June 30, 2025. The number of employees increased by 531 or 9.38% since the number was reported on December 31, 2024.
Employees
6,190
Change
531
Growth
9.38%
Revenue / Employee
$257,593
Profits / Employee
$25,535
Market Cap
19.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6,190 | 531 | 9.38% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Innovent Biologics News
- 3 days ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 3 days ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 2 months ago - ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma - PRNewsWire
- 2 months ago - Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value - PRNewsWire
- 3 months ago - Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints - PRNewsWire